Connor, Clark & Lunn Investment Management Ltd. Ardelyx, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$3.3 - $4.83 $511,288 - $748,340	-154,936 Reduced 30.01%	361,271 $1.47 Million
Q2 2023 Aug 10, 2023	SELL	$3.23 - $4.95 $606,761 - $929,867	-187,852 Reduced 26.68%	516,207 $1.75 Million
Q1 2023 May 09, 2023	BUY	$2.68 - $4.79 $152,663 - $272,857	56,964 Added 8.8%	704,059 $3.37 Million
Q4 2022 Feb 10, 2023	BUY	$1.22 - $2.85 $789,455 - $1.84 Million	647,095 New	647,095 $1.84 Million
Q1 2022 May 12, 2022	SELL	$0.65 - $1.18 $179,529 - $325,914	-276,199 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$0.86 - $1.7 $237,531 - $469,538	276,199 New	276,199 $304,000
Q3 2019 Nov 13, 2019	SELL	$2.15 - $6.28 $89,904 - $262,604	-41,816 Closed	0 $0
Q2 2019 Aug 07, 2019	SELL	$2.49 - $3.73 $64,553 - $96,700	-25,925 Reduced 38.27%	41,816 $112,000
Q1 2019 May 08, 2019	SELL	$1.88 - $3.35 $34,501 - $61,479	-18,352 Reduced 21.32%	67,741 $190,000
Q4 2018 Feb 12, 2019	SELL	$1.66 - $4.16 $54,682 - $137,034	-32,941 Reduced 27.67%	86,093 $154,000
Q3 2018 Nov 13, 2018	SELL	$3.75 - $4.65 $65,625 - $81,375	-17,500 Reduced 12.82%	119,034 $518,000
Q2 2018 Aug 02, 2018	BUY	$3.7 - $5.8 $103,241 - $161,837	27,903 Added 25.69%	136,534 $505,000
Q1 2018 May 14, 2018	BUY	$5.05 - $7.9 $95,950 - $150,100	19,000 Added 21.2%	108,631 $549,000
Q4 2017 Feb 09, 2018	BUY	$4.85 - $7.8 $97,727 - $157,170	20,150 Added 29.0%	89,631 $592,000
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.7 $14,681 - $19,237	3,375 Added 5.11%	69,481 $389,000
Q2 2017 Aug 14, 2017	BUY	N/A	66,106	66,106 $337,000

Others Institutions Holding ARDX

# of Institutions

219

Shares Held

141M

Call Options Held

1.08M

Put Options Held

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $815M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account